Table 3.

Associations of synaptic proteins with PD disease severity

	MoCA Total	Hoehn&Yahr Total	MoCA Drug naive	Hoehn&Yahr Drug naive	MoCA Treated	Hoehn&Yahr Treated
Rab3A	Rho =  0, p = .997, N = 44	Rho = −0.049, p = .743, N = 48	Rho =  −0.150, p = .474, N = 25	Rho = −0.148, p = .436, N = 30	Rho =  .177, p = .469, N = 19	Rho = −0.049, p = .743, N = 18
SNAP25	Rho = −0.007, p = .963, N = 42	Rho = −0.02, p = .897, N = 46	Rho = 0.115, p = .602, N = 23	Rho = −0.205, p = .296, N = 28	Rho = −0.007, p = .963, N = 19	Rho = −0.02, p = .897, N = 18
Neurogranin	Rho = −.358, p = .017, N = 44	Rho = .296, p = .041, N = 48	Rho = −.460, p = .021, N = 25	Rho = .473, p = .008, N = 30	Rho = −.491, p = .033, N = 19	Rho = .216, p = .390, N = 18

Spearman correlations are presented for Rab3A, SNAP25 and neurogranin with cognitive scores assessed by MoCA scores. Results are reported for total PD group, drug naïve group and treated patients with correlation coefficient, p value and number of subjects.